Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-07
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 247.50K shares, a 60.64% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 628.77K shares, a 19.91% increase from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 524.37K shares, a 69.10% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-08 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-08 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-08 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-26 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-07 | 0.00 shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-08-07 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-08 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-08 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-08 | 42.50K shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-26 | 42.50K shares derived: sum of 3 quarters · filed 2026-03-26 | 247.50K shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 42.50K shares derived: sum of 2 quarters · filed 2025-11-06 | 247.50K shares 10-Q · filed 2025-11-06 | 280.50K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 42.50K shares 10-Q · filed 2025-08-07 | 247.50K shares 10-Q · filed 2025-08-07 | 280.50K shares derived: sum of 3 quarters · filed 2025-08-07 | 300.00K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 205.00K shares 10-Q · filed 2025-05-07 | 238.00K shares derived: sum of 2 quarters · filed 2025-05-07 | 257.50K shares derived: sum of 3 quarters · filed 2025-05-07 | 421.05K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | 33.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 52.50K shares derived: sum of 2 quarters · filed 2025-03-20 | 216.05K shares derived: sum of 3 quarters · filed 2025-03-20 | 628.77K shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 19.50K shares 10-Q · filed 2024-11-13 | 183.05K shares derived: sum of 2 quarters · filed 2024-11-13 | 595.77K shares 10-Q · filed 2024-11-13 | 670.87K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 163.55K shares 10-Q · filed 2024-08-08 | 576.27K shares 10-Q · filed 2024-08-08 | 651.37K shares derived: sum of 3 quarters · filed 2024-08-08 | 665.37K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 412.72K shares 10-Q · filed 2024-05-07 | 487.82K shares derived: sum of 2 quarters · filed 2024-05-07 | 501.82K shares derived: sum of 3 quarters · filed 2024-05-07 | 715.95K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 75.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 89.10K shares derived: sum of 2 quarters · filed 2024-03-26 | 303.23K shares derived: sum of 3 quarters · filed 2024-03-26 | 524.37K shares 10-K · filed 2024-03-26 |
| 2022-09-30 | 14.00K shares 10-Q · filed 2023-11-02 | 228.13K shares derived: sum of 2 quarters · filed 2023-11-02 | 449.27K shares 10-Q · filed 2023-11-02 | 2.07M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | 214.13K shares 10-Q · filed 2023-08-08 | 426.57K shares 10-Q · filed 2023-08-08 | 2.06M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.06M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 212.45K shares 10-Q · filed 2023-05-04 | 1.84M shares derived: sum of 2 quarters · filed 2023-05-04 | 1.84M shares derived: sum of 3 quarters · filed 2023-05-04 | 1.85M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | 1.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 1.63M shares derived: sum of 2 quarters · filed 2023-03-23 | 1.64M shares derived: sum of 3 quarters · filed 2023-03-23 | 1.70M shares 10-K · filed 2023-03-23 |
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-14 | 11.59K shares derived: sum of 2 quarters · filed 2022-11-14 | 67.23K shares 10-Q · filed 2022-11-14 | |
| 2021-06-30 | 11.59K shares 10-Q · filed 2022-08-09 | 67.23K shares 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 55.64K shares 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 1.25M shares 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |